Physician profile
Maxwell D Elia
NPI 1902192669
$3,330.33
in general payments reported to CMS, 2019-2025
20 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $109 · 2021: $473 · 2022: $848 · 2023: $689 · 2024: $620 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $871.95 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $586.22 | 2021-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Genentech USA, INC. | $548.80 | 2019-2025 | Vabysmo |
| Horizon Therapeutics Plc | $216.37 | 2021-2023 | Uplizna |
| Astellas Pharma US INC | $164.02 | 2024 | Izervay |
| Alimera Sciences, INC. | $158.20 | 2023-2024 | Yutiq, Iluvien |
| Abbvie INC. | $138.03 | 2019-2025 | |
| Oyster Point Pharma, INC. | $113.53 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $103.62 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $92.03 | 2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Eyepoint US, INC. | $69.73 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.02 | 2021 | |
| Apellis Pharmaceuticals, INC. | $44.05 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $38.50 | 2022-2023 | Envista Mx60 Iol |
| Allergan, INC. | $33.64 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $31.25 | 2024-2025 | |
| Amgen INC. | $26.51 | 2024 | Pavblu |
| Sight Sciences, INC. | $18.92 | 2023 | Tearcare System |
| Takeda Pharmaceuticals U.S.A., INC. | $15.70 | 2024 | Entyvio |
| Sun Pharmaceutical Industries INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell Elia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.